Home > Research > Publications & Outputs > New animal models of Alzheimer's disease that d...
View graph of relations

New animal models of Alzheimer's disease that display insulin desensitization in the brain

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

New animal models of Alzheimer's disease that display insulin desensitization in the brain. / Gao, Chong; Liu, Yueze; Li, Lin et al.
In: Reviews in the Neurosciences, Vol. 24, No. 6, 12.2013, p. 607-615.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Gao C, Liu Y, Li L, Hölscher C. New animal models of Alzheimer's disease that display insulin desensitization in the brain. Reviews in the Neurosciences. 2013 Dec;24(6):607-615. doi: 10.1515/revneuro-2013-0034

Author

Gao, Chong ; Liu, Yueze ; Li, Lin et al. / New animal models of Alzheimer's disease that display insulin desensitization in the brain. In: Reviews in the Neurosciences. 2013 ; Vol. 24, No. 6. pp. 607-615.

Bibtex

@article{2f5b955dfb0b4f8994a97d36a655c1e3,
title = "New animal models of Alzheimer's disease that display insulin desensitization in the brain",
abstract = "Abstract Alzheimer's disease (AD) is a complex neurodegenerative disorder, which involves many underlying pathological processes. Recently, it has been demonstrated that AD also includes impairments of insulin signaling in the brain. Type 2 diabetes is a risk factor for AD, and AD and diabetes share a number of pathologies. The classical hallmarks of AD are senile plaques and neurofibrillary tangles, which consist of amyloid-β and hyperphosphorylated tau. Based on the two hallmarks, transgenic animal models of AD have been developed, which express mutant human genes of amyloid precursor protein, presenilin-1/2, and tau. It is likely that these mouse models are too limited in their pathology. In this work, we describe mouse models that model diabetes and show insulin signaling impairment as well as neurodegenerative pathologies that are similar to those seen in the brains of AD patients. The combination of traditional AD mouse models with induced insulin impairments in the brain may be a more complete model of AD. Interestingly, AD mouse models treated with drugs that have been developed to cure type 2 diabetes have shown impressive outcomes. Based on these findings, several ongoing clinical trials are testing long lasting insulin analogues or GLP-1 mimetics in patients with AD.",
keywords = "Alzheimer{\textquoteright}s disease, amyloid-β , diabetes , db/db mice , exenatide , exendin-4 , high-fat diet , liraglutide , ob/ob mice , streptozocin , tau",
author = "Chong Gao and Yueze Liu and Lin Li and Christian H{\"o}lscher",
year = "2013",
month = dec,
doi = "10.1515/revneuro-2013-0034",
language = "English",
volume = "24",
pages = "607--615",
journal = "Reviews in the Neurosciences",
issn = "0334-1763",
publisher = "WALTER DE GRUYTER GMBH",
number = "6",

}

RIS

TY - JOUR

T1 - New animal models of Alzheimer's disease that display insulin desensitization in the brain

AU - Gao, Chong

AU - Liu, Yueze

AU - Li, Lin

AU - Hölscher, Christian

PY - 2013/12

Y1 - 2013/12

N2 - Abstract Alzheimer's disease (AD) is a complex neurodegenerative disorder, which involves many underlying pathological processes. Recently, it has been demonstrated that AD also includes impairments of insulin signaling in the brain. Type 2 diabetes is a risk factor for AD, and AD and diabetes share a number of pathologies. The classical hallmarks of AD are senile plaques and neurofibrillary tangles, which consist of amyloid-β and hyperphosphorylated tau. Based on the two hallmarks, transgenic animal models of AD have been developed, which express mutant human genes of amyloid precursor protein, presenilin-1/2, and tau. It is likely that these mouse models are too limited in their pathology. In this work, we describe mouse models that model diabetes and show insulin signaling impairment as well as neurodegenerative pathologies that are similar to those seen in the brains of AD patients. The combination of traditional AD mouse models with induced insulin impairments in the brain may be a more complete model of AD. Interestingly, AD mouse models treated with drugs that have been developed to cure type 2 diabetes have shown impressive outcomes. Based on these findings, several ongoing clinical trials are testing long lasting insulin analogues or GLP-1 mimetics in patients with AD.

AB - Abstract Alzheimer's disease (AD) is a complex neurodegenerative disorder, which involves many underlying pathological processes. Recently, it has been demonstrated that AD also includes impairments of insulin signaling in the brain. Type 2 diabetes is a risk factor for AD, and AD and diabetes share a number of pathologies. The classical hallmarks of AD are senile plaques and neurofibrillary tangles, which consist of amyloid-β and hyperphosphorylated tau. Based on the two hallmarks, transgenic animal models of AD have been developed, which express mutant human genes of amyloid precursor protein, presenilin-1/2, and tau. It is likely that these mouse models are too limited in their pathology. In this work, we describe mouse models that model diabetes and show insulin signaling impairment as well as neurodegenerative pathologies that are similar to those seen in the brains of AD patients. The combination of traditional AD mouse models with induced insulin impairments in the brain may be a more complete model of AD. Interestingly, AD mouse models treated with drugs that have been developed to cure type 2 diabetes have shown impressive outcomes. Based on these findings, several ongoing clinical trials are testing long lasting insulin analogues or GLP-1 mimetics in patients with AD.

KW - Alzheimer’s disease

KW - amyloid-β

KW - diabetes

KW - db/db mice

KW - exenatide

KW - exendin-4

KW - high-fat diet

KW - liraglutide

KW - ob/ob mice

KW - streptozocin

KW - tau

U2 - 10.1515/revneuro-2013-0034

DO - 10.1515/revneuro-2013-0034

M3 - Journal article

C2 - 24259244

VL - 24

SP - 607

EP - 615

JO - Reviews in the Neurosciences

JF - Reviews in the Neurosciences

SN - 0334-1763

IS - 6

ER -